China Grants Patent for Self-Developed COVID-19 Vaccine

Joint Development by CanSino and Armed Forces Medical Research Institute
Phase 3 Clinical Trials Conducted Concurrently in Mexico, Saudi Arabia, and Other Countries

[Asia Economy Beijing=Special Correspondent Jo Young-shin] Chinese authorities have granted the first patent for a novel coronavirus disease (COVID-19) vaccine jointly developed by the Chinese pharmaceutical company CanSino Biologics and the Military Medical Research Institute, according to Chinese state media such as the People's Daily and Global Times on the 17th (local time).

The China National Intellectual Property Administration recognized the patent for the COVID-19 vaccine applied for by the team led by Chen Wei, academician of the Military Medical Research Institute of the Military University, and CanSino Biologics.

The China National Intellectual Property Administration granted a patent for the COVID-19 vaccine jointly developed by the Chinese pharmaceutical company CanSino and the Military Medical Research Institute.

The name of the applied vaccine is "A new form of retrovirus vaccine using a human replication-defective adenovirus as a vector."

The joint research team explained the significance by stating, "The granting of the patent further confirms the efficacy and safety of the vaccine."

Yang Zanchui, a professor in the Department of Pathogen Biology at Wuhan University Hospital in China, said, "The genetic sequence of the virus is very important for vaccine development and can also be regarded as intellectual property."

Xu Xinming, an intellectual property specialist lawyer based in Beijing, said, "China has a relatively strict and complete patent examination system," adding, "To be granted a patent, the technology or product must be fundamentally different from existing similar technologies or products."

Chinese media emphasized the significance by stating, "The official granting of the patent will increase the credibility of the COVID-19 vaccine developed by China, especially in the international community."

In a paper published last month in the medical journal The Lancet, the joint research team revealed that the COVID-19 vaccine successfully induced antibody formation in phase 2 clinical trials.

The joint research team administered the COVID-19 vaccine to 508 adult test subjects aged 18 to 83, and most of the subjects generated a neutralizing antibody immune response.

The Global Times added that phase 3 clinical trials of the COVID-19 vaccine are scheduled to be conducted overseas in Mexico, Saudi Arabia, Chile, Brazil, Russia, and other countries.

This content was produced with the assistance of AI translation services.